We work hard to bring you the stories about the life science community in North Carolina. Every once in a while, we add a little news of our own. Read some of those stories below, or check out some of our perspectives on our staff blog.
Bill Dean, the Director of the Piedmont Triad Research Park has been named Chairman of the newly formed North Carolina Research Parks Network organization. As of January 2009, Bill will chair the Network, a coalition of seven leading science parks located across the state of North Carolina.
Research Triangle Park-based SCYNEXIS has reported positive results from a Phase I clinical trial for its lead oral antiviral drug candidate for treating adults with chronic hepatitis C virus (HCV) infection.
The experimental medicine, dubbed SCY-635, represents a new class of drugs called cyclophilin inhibitors. They're a family of enzymatic proteins related to the more well-known drug cyclosporine that has been used for decades to prevent organ rejection after transplants.
Durham-based Expression Analysis will promote its recent purchase of an Illumina genome analyzer at the International Plant & Animal Genome Conference in San Diego next week, as proof of its entry into the agricultural market.
The 8-year-old provider of genomic services for clinical trials and research intends to use its booth at the show to demonstrate ways agricultural scientists can accelerate their discoveries using Expression Analysis in their biological research.
Research Triangle Park-based Liquidia Technologies and pharmaceutical company Abbott have signed a collaborative agreement to use Liquidia nanotechnology to deliver cancer therapy.
Liquidia, a privately held nanotechnology company co-founded in 2004 on the discoveries of Professor Joseph DeSimone, Ph.D., and colleagues at the University of North Carolina at Chapel Hill, uses a protein particle fabrication method licensed from UNC.
Durham-based Chimerix has started Phase II clinical trials of its oral anti-viral drug candidate, CMX001, after finding positive results in Phase I tests involving 84 healthy volunteers.
Raleigh-based BioDelivery Sciences has sold another round of marketing rights for its lead product, ONSOLIS, allowing its Swedish commercial partner, Meda, to sell the drug everywhere but Taiwan and South Korea.
The sale, for a one-time cash payment of $3 million, expanded an earlier marketing agreement giving Meda rights to sell ONSOLIS, a pain therapy using BioDelivery's proprietary delivery system involving a drug-impregnanted film held against the inside of the cheek.
Industry Expansions May Create 3,100 New Jobs
By Barry Teater
Vice President, Corporate Communications (Barry no longer works at the Center)
North Carolina, already the world's leading center for contract research organizations, is entering a renaissance era of CRO company growth and job creation.